- South Korea Pharma inlicensing strategy provides financing opportunites to development stage companies with novel late stage products and devices
- Business Opportunities and Analysis reports provide new ideas and directions
- BDSI and TTY enter into a licensing agreement for Bema Fentanyl for the Taiwan market
- Alfresa Pharmaceutical Corporation of Japan entered into a licensing and supply agreement for development and marketing of tetrabenazine (Xenazine®) in Japan with Canada's Biovail Corporation
- BDSI and KunWha Pharmaceutical Co. entered into a licensing agreement for Bema Fentanyl for the South Korean market
CONTACT
Contact ProPharma Partners
U.S.A. Headquarters
 |
ProPharma Partners International, Inc. |
|---|---|
| Phone: | 510 681 4445 |
| Fax: | 707 258 1134 |
Europe
 |
ProPharma Partners Limited The Courtyard 30 Worthing Road Horsham West Sussex RH12 1SL U.K. |
|---|---|
| Phone: | 01403 793769 |
Japan
 |
BioLink International, Inc. Daiichi Enoki Bldg. 4F 5-3-1, Toranomon, Minato-ku, Tokyo 105-0001 Japan |
|---|---|
| Phone: | 81 3 5777 0271 |
| Fax: | 81 3 5472 7076 |
ProPharma Partner Emails
(click on any of the names below to send an email)
 |
|
|---|---|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
